|
Vaccine Detail
Marburg virus recombinant vector vaccine CAdVax-Panfilo |
Vaccine Information |
- Vaccine Name: Marburg virus recombinant vector vaccine CAdVax-Panfilo
- Target Pathogen: Marburg Virus
- Target Disease: Hemorrhagic fever
- Vaccine Ontology ID: VO_0004388
- Type: Recombinant vector vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Macaque
- GP from Musoke Marburgvirus
gene engineering:
- Type: Recombinant vector construction
- Description: This DNA vaccine expressed MARV Musoke GP (Swenson et al., 2008).
- Detailed Gene Information: Click Here.
- NP from Marburg virus Musoke
gene engineering:
- Type: Recombinant vector construction
- Description: This DNA vaccine expressed MARV Musoke NP (Swenson et al., 2008).
- Detailed Gene Information: Click Here.
- GP from Marburg virus Ci67
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- GP from Marburg virus Ravn
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- NP
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- GP
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- SGP
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Macaque Response
- Vaccine Immune Response Type: VO_0000286
- Immune Response: All vaccinated animals from groups 1(challenged with 1,000 PFU MARV Musoke) and 2 (challenged with the same dose of ZEBOV) mounted strong antibody titers against all five filoviruses with similar kinetics (Swenson et al., 2005).
- Efficacy: Vaccination of NHP with CAdVax-Panfilo was 100% protective against challenge with multiple filovirus species, including ZEBOV, SEBOV, MARV Musoke, and MARV Ci67 (Swenson et al., 2005).
|
References |
Swenson et al., 2005: Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine. 2005; 23(23); 3033-3042. [PubMed: 15811650].
Swenson et al., 2008: Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clinical and vaccine immunology : CVI. 2008; 15(3); 460-467. [PubMed: 18216185].
|
|